These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 10653927)
1. Low density lipoprotein cholesterol: is lower better? Leiter LA Can J Cardiol; 2000 Jan; 16 Suppl A():20A-2A. PubMed ID: 10653927 [TBL] [Abstract][Full Text] [Related]
2. [Statins in primary prevention of coronary heart disease]. Paulweber B Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004 [TBL] [Abstract][Full Text] [Related]
3. Low density lipoprotein cholesterol lowering: are the treatment guidelines still appropriate? Deslypere JP Int J Clin Pract; 2000 Jun; 54(5):307-13. PubMed ID: 10954957 [TBL] [Abstract][Full Text] [Related]
4. Cholesterol: precursor to many lipid disorders. Jones PH Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815 [TBL] [Abstract][Full Text] [Related]
5. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
6. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Rosenson R; Lloyd-Jones D; Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256 [TBL] [Abstract][Full Text] [Related]
7. [The role of cholesterol-lowering drugs in prevention of coronary heart disease]. Skałuba Z; Undas R Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881 [TBL] [Abstract][Full Text] [Related]
8. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
9. [New results in the management of hypercholesterolemia]. Sármán B Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867 [TBL] [Abstract][Full Text] [Related]
10. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Garmendia F; Brown AS; Reiber I; Adams PC Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
12. What do the statin trials tell us? Waters DD Am J Manag Care; 2001 May; 7(5 Suppl):S138-43. PubMed ID: 11383375 [TBL] [Abstract][Full Text] [Related]
13. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. Ballantyne CM Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009 [TBL] [Abstract][Full Text] [Related]
14. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
16. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A; Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). McPherson R; Angus C; Murray P; Genest J; Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H; Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314 [TBL] [Abstract][Full Text] [Related]
19. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A; Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888 [TBL] [Abstract][Full Text] [Related]
20. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]